Table 3.

UVA and MVA of risk groups and survival

Risk groups	UVA				MVAa
	OS		PFS		OS		PFS
	HR (CI)	p value	HR (CI)	p value	HR (CI)	p value	HR (CI)	p value
Very poor risk: Risk score = 3–4 (n = 13)	37.72 (4.76–298.70)	<.001b	3.87 (1.50–9.96)	.005b	29.50 (3.64–238.90)	.002b	2.80 (1.10–7.11)	.030b
					Median survival: 4.2 months		Median survival: 2.6 months
Poor risk: Risk score = 2 (n = 28)	8.49 (1.11–64.75)	.039b	2.13 (0.90–5.02)	.085	6.58 (0.84–51.68)	.073	1.36 (0.55–3.33)	.506
					Median survival: 16.9 months		Median survival: 4.5 months
Intermediate risk: Risk score = 1 (n = 45)	4.22 (0.55–32.17)	.165	1.40 (0.61–3.19)	.422	3.75 (0.49–28.57)	.203	1.70 (0.73–3.94)	.218
					Median survival: 29.7 months		Median survival: 6.1 months
Good risk: Risk score = 0 (n = 13)	1		1		1		1
					Median survival: Not reached		Median survival: 12.3 months

^aMVA controlled for gender, race, International Metastatic Renal Cell Carcinoma Database Consortium risk group, number of distant metastases, age, clear cell renal cell carcinoma histology, programmed cell death protein‐1 monotherapy, and number of prior lines of systemic therapy.

^bStatistical significance at α < .05.

Abbreviations: CI, 95% confidence interval; HR, hazard ratio; MVA, multivariate analysis; OS, overall survival; PFS, progression‐free survival; UVA, univariate analysis.